A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Navarixin (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 08 Jan 2019 Planned End Date changed from 9 Aug 2019 to 8 Jan 2020.
- 08 Jan 2019 Planned primary completion date changed from 9 Aug 2019 to 8 Jan 2020.
- 13 Apr 2018 Status changed from not yet recruiting to recruiting.